<h2 dir="ltr">Cell and Gene Therapies in Rare Disorders</h2>
Cell and Gene Therapies in Rare Disorders are transforming the treatment landscape by targeting the underlying genetic cause of disease rather than merely managing symptoms. Advances in viral vectors, gene editing, stem cell technologies, and cell engineering have enabled the development of durable, potentially curative therapies across a broad range of inherited, neuromuscular, hematologic, ocular, and metabolic disorders.
<h2 dir="ltr">Cell and Gene Therapies in Rare Disorders Epidemiology Segmentation</h2>
<ul>
<li dir="ltr" aria-level="1">
Total Prevalent Cases of Selected Indications
</li>
<li dir="ltr" aria-level="1">
Total Indication-wise Eligible Cases
</li>
<li dir="ltr" aria-level="1">
Total Indication-wise Treated Cases
</li>
<li dir="ltr" aria-level="1">
Target Patient Pool Analysis
</li>
</ul>
<h2 dir="ltr">Cell and Gene Therapies in Rare Disorders Epidemiology</h2>
<ul>
<li dir="ltr" aria-level="1">
The eligible patient population for cell and gene therapies continues to expand across multiple rare disorders as diagnostic capabilities and genetic testing become more widely adopted.
</li>
<li dir="ltr" aria-level="1">
In the United States during 2025, the estimated prevalent patient populations included approximately 274,000 cases of Retinitis Pigmentosa, 104,000 cases of Limbal Stem Cell Deficiency, 89,000 cases of Sickle Cell Disease, 30,000 cases of Amyotrophic Lateral Sclerosis (ALS), 17,500 cases of Duchenne Muscular Dystrophy (DMD), and 13,000 cases of Spinal Muscular Atrophy (SMA).
</li>
<li dir="ltr" aria-level="1">
Fabry disease affects an estimated 1 in 40,000&ndash;60,000 males in the United States, while Hemophilia B is nearly one-fifth as prevalent as Hemophilia A.
</li>
<li dir="ltr" aria-level="1">
The majority of recombinant adeno-associated virus (rAAV) gene therapy programs continue to target the liver, central nervous system, and striated muscles, where AAV vectors have demonstrated efficient and durable gene delivery.
</li>
</ul>
<h2 dir="ltr">Cell and Gene Therapies in Rare Disorders Market</h2>
<ul>
<li dir="ltr" aria-level="1">
Within the 7 Major Markets, the United States accounted for approximately 40% of the total Cell and Gene Therapies in Rare Disorders market in 2025.
</li>
<li dir="ltr" aria-level="1">
The market size across the 7MM was estimated at approximately USD 5 billion in 2025.
</li>
<li dir="ltr" aria-level="1">
The market is projected to grow at a CAGR of approximately 15% during the forecast period (2026&ndash;2036).
</li>
<li dir="ltr" aria-level="1">
Market expansion is expected to be driven by the growing number of approved gene therapies, increasing physician adoption, expansion into additional rare disease indications, one-time potentially curative treatment approaches, and continued investment in advanced genetic medicine platforms.
</li>
</ul>
<h2 dir="ltr">Cell and Gene Therapies in Rare Disorders Market Drivers</h2>
<ul>
<li dir="ltr" aria-level="1">
Rising prevalence and improved diagnosis of rare genetic disorders continue to expand the eligible treatment population.
</li>
<li dir="ltr" aria-level="1">
Increasing investment in cell and gene therapy research is accelerating innovation across multiple rare disease indications.
</li>
<li dir="ltr" aria-level="1">
A robust competitive landscape with numerous late-stage programs is strengthening future market growth.
</li>
<li dir="ltr" aria-level="1">
Growing healthcare expenditure and favorable regulatory support are facilitating broader adoption of advanced therapies.
</li>
</ul>
<h2 dir="ltr">Cell and Gene Therapies in Rare Disorders Market Barriers</h2>
<ul>
<li dir="ltr" aria-level="1">
High treatment costs and affordability challenges continue to restrict patient access.
</li>
<li dir="ltr" aria-level="1">
Manufacturing complexity and scalability limitations remain major obstacles to widespread commercialization.
</li>
<li dir="ltr" aria-level="1">
Delivery challenges affecting tissue targeting and treatment consistency continue to impact therapeutic outcomes.
</li>
<li dir="ltr" aria-level="1">
Limited long-term safety and durability data create uncertainty regarding lifelong treatment benefits.
</li>
</ul>
<h2 dir="ltr">Emerging Cell and Gene Therapies in Rare Disorders</h2>
<ul>
<li dir="ltr" aria-level="1">
Deramiocel (CAP-1002)
</li>
<li dir="ltr" aria-level="1">
RGX-121
</li>
<li dir="ltr" aria-level="1">
ST-920
</li>
<li dir="ltr" aria-level="1">
And others
</li>
</ul>
<h2 dir="ltr">Key Cell and Gene Therapies in Rare Disorders Companies</h2>
<ul>
<li dir="ltr" aria-level="1">
Capricor Therapeutics
</li>
<li dir="ltr" aria-level="1">
Nippon Shinyaku
</li>
<li dir="ltr" aria-level="1">
REGENXBIO
</li>
<li dir="ltr" aria-level="1">
Sangamo Therapeutics
</li>
<li dir="ltr" aria-level="1">
Spark Therapeutics
</li>
<li dir="ltr" aria-level="1">
CSL
</li>
<li dir="ltr" aria-level="1">
uniQure
</li>
<li dir="ltr" aria-level="1">
Bluebird Bio
</li>
<li dir="ltr" aria-level="1">
Novartis
</li>
<li dir="ltr" aria-level="1">
Coave Therapeutics
</li>
<li dir="ltr" aria-level="1">
GenSight Biologics
</li>
<li dir="ltr" aria-level="1">
Ultragenyx
</li>
<li dir="ltr" aria-level="1">
Pfizer
</li>
<li dir="ltr" aria-level="1">
Roche
</li>
<li dir="ltr" aria-level="1">
4D Molecular Therapeutics
</li>
<li dir="ltr" aria-level="1">
Astellas Gene Therapies
</li>
<li dir="ltr" aria-level="1">
Actus Therapeutics
</li>
<li dir="ltr" aria-level="1">
Nanoscope Therapeutics
</li>
<li dir="ltr" aria-level="1">
Ocugen
</li>
<li dir="ltr" aria-level="1">
jCyte
</li>
<li dir="ltr" aria-level="1">
Amicus Therapeutics
</li>
<li dir="ltr" aria-level="1">
BrainStorm Cell Therapeutics
</li>
<li dir="ltr" aria-level="1">
Editas Medicine
</li>
<li dir="ltr" aria-level="1">
Abeona Therapeutics
</li>
<li dir="ltr" aria-level="1">
Ishin Pharma
</li>
<li dir="ltr" aria-level="1">
And others.
</li>
</ul>
&nbsp;

Cell and Gene Therapies in Rare Disorders Market

Cell and Gene Therapies in Rare Disorders Infographic

Cell and Gene Therapies in Rare Disorders Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape